Investor Alert: Pomerantz Law Firm Investigates EyePoint, Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by EyePoint, Inc. (NASDAQ: EYPT) and certain of its officers and directors on behalf of investors. The investigation follows a significant drop in the company's stock price after it announced disappointing results from its Phase 3 clinical trial for DURAVYU™. On August 17, 2026, EyePoint reported that the topline data from the LUGANO trial did not meet expectations compared to Regeneron Pharmaceuticals' Eylea. This led to a sharp decline in stock price—falling $9.88 per share (or 66.98%) on the same day. Pomerantz LLP, known for its work in securities class actions and corporate litigation, is seeking investors who may be interested in joining an ongoing investigation.
Topics: clinical_trial_results securities_fraud stock_price_drop